- Advertise
- About OncLive
- Editorial Board
- MJH Life Sciences brands
- Contact Us
- Privacy
- Terms & Conditions
- Do Not Sell My Information
2 Clarke Drive
Suite 100
Cranbury, NJ 08512
© 2024 MJH Life Sciences™ and OncLive - Clinical Oncology News, Cancer Expert Insights. All rights reserved.
Latest Conference Articles
The OncLive® Conference page includes a listing of all conferences covered by OncLive®, including the ASCO, ESMO, SITC, EHA, ASH, and SABCS annual meetings, as well as the Chemotherapy Foundation Symposium and Miami Breast Cancer Conference, among many others. Conference coverage incorporates articles and interviews in written and video format.
Pembrolizumab Studies Show Disparate Data on Link Between AE and Response in Multiple Myeloma
June 2nd 2018, 9:57pm
Pembrolizumab (Keytruda) yielded inconsistent results regarding the relationship between immune-related adverse events and objective response in multiple myeloma.
Microsatellite Instability Status Links to Lynch Syndrome in Broad Array of Cancers
June 2nd 2018, 9:48pm
Microsatellite instability-high tumors are more likely to be associated with the presence of Lynch syndrome. Yet, 45% of patients with cancers not typically identified with Lynch syndrome actually qualify for germline genetic testing.
Only Modest Benefit Seen With Taselisib in PIK3CA-Mutant Breast Cancer
June 2nd 2018, 9:34pm
Treatment with taselisib in combination with fulvestrant provided a modest progression-free survival benefit of 2 months compared with fulvestrant alone in patients with estrogen receptor–positive, PIK3CA-mutant locally advanced or metastatic breast cancer
Once Weekly Carfilzomib Superior in Relapsed/Refractory Myeloma
June 2nd 2018, 9:09pm
Carfilzomib (Kyprolis) administered once weekly at 70 mg/m2 with dexamethasone resulted in a prolonged PFS compared with the standard twice-weekly schedule in patients with relapsed/refractory multiple myeloma.
Atezolizumab Plus Chemo Extends PFS in Frontline Squamous NSCLC
June 2nd 2018, 8:55pm
The addition of atezolizumab (Tecentriq) to frontline carboplatin and nab-paclitaxel (Abraxane) delayed the risk of progression or death by 29% compared with chemotherapy alone for patients with advanced squamous NSCLC.
LOXO-292 Shows Impressive Response Rates for RET-Positive Tumors
June 2nd 2018, 8:22pm
The highly-selective RET inhibitor LOXO-292 demonstrated robust clinical activity across RET-altered solid tumors, including in patients with brain metastases and the RET V804M gatekeeper mutation.
Ibrutinib/Rituximab Reduces Progression Risk by 80% in Waldenstrom Macroglobulinemia
June 2nd 2018, 6:58pm
Adding ibrutinib to rituximab lowered the risk of disease progression or death by 80% versus rituximab alone in patients with Waldenström macroglobulinemia.
bb2121 Adds Nearly 1 Year of PFS for Heavily Pretreated Myeloma
June 2nd 2018, 9:43am
bb2121 had a median progression-free survival of 11.8 months and a median duration of response of 10.8 months for patients with relapsed/refractory heavily pretreated multiple myeloma.
Dr. Mohile on Using a Geriatric Assessment in Older Patients With Cancer
June 2nd 2018, 5:24am
Supriya Gupta Mohile, MD, MS, professor of medicine and surgery, James Wilmot Cancer Institute, director, Geriatric Oncology Clinic, University of Rochester, discusses pooled findings with a geriatric assessment for older patients with cancer in an interview with OncLive during the 2018 ASCO Annual Meeting.
Dr. George on Results of Abi Race Trial in Prostate Cancer
June 2nd 2018, 4:52am
Daniel J. George, MD, professor of medicine, surgery, member, Duke Cancer Institute, discusses the results of the prospective multicenter Abi Race trial, which compared outcomes of African-American and Caucasian patients with metastatic castration-resistant prostate cancer (mCRPC) treated with abiraterone acetate (Zytiga) and prednisone.
Pomalidomide Triplet Extends PFS in Relapsed/Refractory Myeloma
June 2nd 2018, 4:22am
Adding pomalidomide (Pomalyst) to bortezomib (Velcade) and low-dose dexamethasone reduced the risk of disease progression or death by 39% in patients with relapsed/refractory multiple myeloma with prior exposure to lenalidomide.
Venetoclax/Carfilzomib Combo Highly Effective for t(11;14) Myeloma
June 2nd 2018, 3:44am
The addition of venetoclax to carfilzomib and dexamethasone demonstrated a 100% objective response rate with a very good partial response or better rate of 86% for patients with relapsed/refractory t(11;14) multiple myeloma.
Colorectal Cancer Treatment Twice as Costly in US Than Canada, Despite Similar Outcomes
June 2nd 2018, 3:26am
A study that compared costs of treatment for metastatic colorectal cancer in Western Washington and the province of British Columbia in Canada found that prices were more than twice as high for the US patients than for their Canadian counterparts, with no significant difference in outcomes.
Geriatric Assessment Improves Patient Satisfaction, Patient-Oncologist Communication
June 2nd 2018, 2:26am
Evaluating health-related concerns as part of routine care for elderly patients with advanced cancer significantly improved doctor-patient communication and patient satisfaction.
Black Men May Fare Better Than White Men With Standard mCRPC Therapy
June 2nd 2018, 1:27am
Black men with metastatic castration-resistant prostate cancer may experience greater benefits from chemotherapy and hormone-targeting treatment than their white counterparts.
Compared With Men, Women With Head and Neck Cancer Undertreated
June 1st 2018, 11:27pm
Women with head and neck cancer may be severely undertreated and have higher death rates compared with their male counterparts.
ASCO 2018: Top Oncologists Select Key, Practice-Changing Abstracts
May 30th 2018, 8:07pm
Key opinion leaders spoke with OncLive ahead of the 2018 ASCO Annual Meeting to share the top abstracts they believe could have the greatest impact on clinical practice and patient outcomes across lymphomas, gastrointestinal cancers, genitourinary cancers, and lung cancer.
NGS Established as Most Cost-Effective Genetic Test for Metastatic NSCLC
May 17th 2018, 1:00am
Next-generation sequencing in metastatic non-small cell lung cancer can save Center for Medicare and Medicaid Services payers $1.4 million to $2.1 million.
Symptom Tracking System Reduces Severity in Patients With Head and Neck Cancer
May 17th 2018, 1:00am
Patients who used mobile and sensor technology to track their symptoms demonstrated reduced severity of their symptoms compared with patients who received standard care.
Despite USPSTF Recommendations and Medicaid Coverage, Data Show Low Lung Cancer Screening Rate
May 17th 2018, 1:00am
A total 1.9% of more than 7.6 million current and former heavy smokers in the United States underwent lung cancer screening in 2016, suggesting that it remains inadequate despite USPTF recommendations.